Loading clinical trials...
Loading clinical trials...
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
Conditions
Interventions
EV71 vaccine
Placebo
Locations
8
Taiwan
Changhua Christian Hospital
Changhua, Taiwan
National Taiwan University Hospital HsinChu Branch
Hsinchu, Taiwan
China Medical University Hospital
Taichung, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Start Date
June 27, 2018
Primary Completion Date
August 30, 2024
Completion Date
December 31, 2024
Last Updated
August 28, 2024
NCT06922474
NCT04431050
NCT01129232
NCT02777411
NCT00426699
Lead Sponsor
Enimmune Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions